Import from '@womanrx/components'

Egrifta (Tesamorelin) Compounded vs Branded: What Women Need to Know Before Choosing

What Tesamorelin Actually Is and How It Works in Women

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors, stimulating the pulsatile release of endogenous growth hormone (GH), which in turn raises insulin-like growth factor-1 (IGF-1). The downstream effect is preferential reduction of visceral adipose tissue rather than subcutaneous fat.

This mechanism matters differently for women.

How Female Hormonal Status Changes the GH Axis

Women have naturally higher GH pulse amplitude than men across the reproductive years, driven partly by estrogen's sensitizing effect on pituitary somatotrophs. When estrogen drops during perimenopause and postmenopause, GH secretion and IGF-1 levels fall more steeply in women than in men of comparable age. That means a GHRH-stimulating drug like tesamorelin operates on a pituitary that is already hormonally altered by menopausal status.

Oral estrogen (but not transdermal) further suppresses hepatic IGF-1 production through first-pass liver metabolism. If you are taking oral hormone therapy and your clinician is monitoring IGF-1 on tesamorelin, that suppression may blunt the measurable IGF-1 rise even when the drug is working at the pituitary level. Transdermal estrogen does not carry this effect to the same degree.

Women With PCOS and Insulin Resistance

Women with polycystic ovary syndrome (PCOS) often have altered GH pulsatility and elevated IGF-1 activity relative to reproductive-age peers without PCOS. Tesamorelin's IGF-1-raising effect requires careful monitoring in this group. No dedicated PCOS tesamorelin trial exists, and clinicians are extrapolating from the broader HIV-lipodystrophy and GH-deficiency literature. This is an evidence gap you deserve to know about.

The Clinical Trial Foundation: Falutz et al. And What It Means for Women

The key data for Egrifta comes from a landmark randomized controlled trial published in the New England Journal of Medicine in 2007. Julian Falutz and colleagues enrolled 412 HIV-infected adults with abdominal fat accumulation and randomized them to tesamorelin 2 mg subcutaneously once daily or placebo for 26 weeks.

The result: a statistically significant 15% reduction in visceral adipose tissue (VAT) in the tesamorelin arm, measured by CT scanning, compared to essentially no change in the placebo group. Trunk fat ratio and patient-reported abdominal appearance scores also improved.

What the Trial Did Not Tell Us About Women Specifically

Women made up a minority of participants in this trial, reflecting the historical enrollment pattern in HIV drug studies. The trial did not stratify results by menopausal status, oral versus transdermal hormone therapy use, or reproductive history. The 15% VAT reduction figure is therefore a mixed-sex aggregate, and the female-specific effect size was not separately reported with the statistical power to draw firm conclusions.

This is a direct evidence gap. Women in the trial were assumed to respond similarly to men, which may not hold once hormonal differences in GH pulsatility and IGF-1 production are accounted for. Your clinician should discuss this uncertainty with you rather than presenting the 15% figure as equally applicable to all women.

A 2010 extension study by Falutz et al. showed that 26 additional weeks of tesamorelin maintained the visceral fat reduction, and discontinuation led to VAT returning toward baseline over 12 weeks, reinforcing that this is a treatment requiring continued use rather than a one-time course.

Branded Egrifta: Formulation, Dosing, and What FDA Approval Actually Guarantees

Egrifta SV (the current reformulated version, replacing the original Egrifta) is supplied as a 2 mg/vial lyophilized powder requiring reconstitution with sterile water. The approved dose is 2 mg injected subcutaneously into the abdomen once daily. Injection sites should be rotated; avoid navel and scar tissue.

FDA approval means the manufacturer demonstrated to the agency's standard that this specific product:

• Contains what the label says in the stated concentration
• Is sterile and free from endotoxins
• Meets stability specifications throughout shelf life
• Was tested in a controlled clinical trial with a defined patient population

That is not a small guarantee. It means every vial of branded Egrifta you receive has passed lot-release testing before it leaves the manufacturer.

Monitoring Required on Egrifta

Whether branded or compounded, tesamorelin requires periodic monitoring:

• IGF-1 levels: Check at baseline, then approximately 3 months into therapy. An IGF-1 above the age- and sex-adjusted upper limit of normal suggests the dose may need reconsideration.
• Glucose and HbA1c: Tesamorelin can cause transient insulin resistance, so fasting glucose or HbA1c should be checked at baseline and periodically. Women with PCOS or a history of gestational diabetes carry additional baseline risk.
• Fluid retention markers: Edema, arthralgias, and carpal tunnel symptoms are GH-class effects that can occur in women, particularly if estrogen levels are in flux.

Compounded Tesamorelin: What the Term Actually Covers

"Compounded tesamorelin" refers to tesamorelin peptide prepared by a compounding pharmacy outside the FDA drug-approval pathway. These preparations are not FDA-approved, and the FDA has not authorized tesamorelin as a bulk substance for compounding under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

That single fact carries real consequences.

Purity, Potency, and Sterility Risks

A compounding pharmacy making tesamorelin purchases the active pharmaceutical ingredient (API) from a raw-material supplier, typically overseas. The FDA does not routinely inspect these API sources to the same standard as licensed drug manufacturers. Independent testing of compounded peptides has found meaningful variability in actual peptide content, including batches that contained significantly less active drug than labeled, degradation products, and in rare cases, microbial contamination.

For a peptide that relies on precise receptor binding to stimulate a pulsatile hormonal cascade, dose inaccuracy is not trivial. If you are receiving 60% of the stated dose, you may see little visceral fat change and conclude the drug does not work for you. If you are receiving 140% of the stated dose, you run IGF-1 levels that could fall outside the safe range without knowing it.

The Legal and Regulatory Picture in 2025

The FDA has taken enforcement action against compounding pharmacies preparing peptides including tesamorelin analogs. In 2024, the agency issued guidance reinforcing that tesamorelin is not on the 503A bulk substances list, meaning compounding pharmacies operating under the traditional small-scale exemption cannot legally compound it. Some 503B outsourcing facilities operate under different rules but are still prohibited from compounding copies of approved drugs when a commercially available alternative exists.

This legal gray area shifts constantly. If a pharmacy is offering compounded tesamorelin and citing regulatory compliance, ask them specifically under which FDA framework they are operating, and request their most recent certificate of analysis from a third-party lab.

Cost and Access Comparison

Branded Egrifta SV carries a list price that can exceed $4,000 per month without insurance. For HIV-positive women with the on-label indication, manufacturer patient assistance programs and insurance coverage through most major plans may dramatically reduce out-of-pocket cost.

Compounded tesamorelin is often offered at $150 to $400 per month through telehealth platforms. That price difference is real. But it reflects the absence of the R&D investment, clinical-trial costs, FDA-review costs, and lot-release testing that go into the branded product.

Pregnancy, Lactation, and Contraception: Non-Negotiable Safety Information

Tesamorelin is contraindicated in pregnancy. This applies to both branded Egrifta and any compounded formulation.

Why Pregnancy Contraindication Matters

GHRH analogs act on fetal pituitary somatotrophs. Animal studies with tesamorelin showed embryofetal toxicity at doses relevant to human exposure. No adequate controlled human data exist in pregnant women, and given the mechanism, no safe dose in pregnancy has been established. Egrifta's FDA prescribing information assigns it to former Category X (now described under the 2015 PLLR labeling system as contraindicated based on animal data and mechanism of action).

If you are of reproductive age and prescribed tesamorelin, you need reliable contraception throughout treatment. "Reliable" in this context means a method with a failure rate below 1% with typical use: an intrauterine device (hormonal or copper), a hormonal implant, or consistent combined oral contraceptive use with a backup method if adherence is uncertain.

Stop tesamorelin at least one full menstrual cycle before any planned conception attempt, and longer if your clinician advises based on IGF-1 normalization. Inform your prescriber immediately if you become pregnant while on tesamorelin.

Lactation

The transfer of tesamorelin into human breast milk has not been studied. Given that GH axis stimulation affects multiple metabolic pathways and that the drug's effects on a breastfeeding infant's growth axis are unknown, breastfeeding is not recommended during tesamorelin therapy. Discuss timing with your clinician if you are in the postpartum period and considering treatment.

Perimenopausal and Postmenopausal Women

Women in perimenopause are often trying to conceive or may not have confirmed cessation of ovulation. Do not assume perimenopausal status equals effective contraception. Current ACOG guidance states that women should use contraception until 12 consecutive months without a menstrual period confirm postmenopause. If you are in the perimenopausal transition and prescribed tesamorelin, you need contraception.

Who This Drug Is Right For, and Who Should Think Carefully

The following framework is designed to help women at different life stages evaluate tesamorelin candidacy. It does not replace a clinical conversation.

Women Who May Be Appropriate Candidates (Branded Egrifta)

• HIV-positive women with documented visceral lipodystrophy on antiretroviral therapy
• Women with a stable, non-pregnant reproductive status and reliable contraception in place
• Postmenopausal women with HIV lipodystrophy and no history of active malignancy
• Women without uncontrolled diabetes (HbA1c <8% is a reasonable threshold many clinicians use before initiating)

Women Who Should Not Use Tesamorelin

• Pregnant women (any trimester, any formulation)
• Breastfeeding women
• Women with active or history of pituitary tumor or hypothalamic disease
• Women with active malignancy or those receiving cancer therapy with curative intent
• Women with severe or uncontrolled diabetes: tesamorelin's insulin-resistance effect adds metabolic burden
• Women with a history of hypersensitivity to tesamorelin or mannitol (present in the formulation)

Off-Label Use in Women Without HIV: The Evidence Problem

Tesamorelin is increasingly prescribed or sought off-label for visceral fat reduction in non-HIV women, including those with metabolic syndrome, menopause-related central adiposity, and PCOS-related abdominal fat accumulation. There is no published randomized trial supporting tesamorelin for any of these indications in women without HIV. The physiological rationale exists, but the evidence does not. A woman considering tesamorelin off-label should understand she is taking a drug with real risks and costs on the basis of mechanism alone, not proven outcomes in her specific situation.

Tesamorelin Across the Female Life Stages

Reproductive Years (Ages Roughly 18 to 40)

GH pulsatility is highest during the reproductive years. Estrogen amplifies GH release. Women in this life stage who have HIV lipodystrophy and are candidates for tesamorelin must have contraception confirmed before the first dose. Menstrual cycle phase has not been formally studied as a modifier of tesamorelin response, but luteal-phase progesterone effects on fluid retention may compound edema side effects around that phase of the cycle.

Perimenopause (Typically Ages 45 to 55, Variable)

As ovarian function becomes irregular, GH pulsatility drops and visceral fat deposition accelerates independent of any HIV-related process. This life stage represents the population most frequently asking about off-label tesamorelin. The data gap here is significant. IGF-1 naturally falls in perimenopause, which may make women in this stage more sensitive to tesamorelin's IGF-1-raising effect and more vulnerable to side effects at standard doses. Some clinicians start at a lower dose and titrate. No published trial supports this approach specifically; it is clinical extrapolation.

Postmenopause

After 12 consecutive months without menses, contraception requirements for tesamorelin no longer apply from a pregnancy-prevention standpoint. Postmenopausal women on oral estrogen therapy need IGF-1 interpreted with the suppressive effect of first-pass hepatic metabolism in mind. Transdermal estrogen users do not have this complication. Bone health monitoring is also relevant: GH and IGF-1 have anabolic effects on bone, which may be a secondary benefit in postmenopausal women with osteopenia, though this has not been studied as a primary endpoint in tesamorelin trials.

Side Effects in Women: What to Expect and What to Report

The most common adverse effects reported in the Falutz NEJM trial and the Egrifta prescribing information include:

• Injection-site reactions: Erythema, pruritus, pain at the injection site. Rotating sites across the abdomen helps.
• Fluid retention: Peripheral edema, arthralgias, myalgias. These are GH-class effects and tend to be more pronounced at treatment initiation.
• Carpal tunnel syndrome: More common in women generally, and the GH-mediated fluid retention may make this worse. Report new tingling or numbness in hands promptly.
• Glucose elevation: Tesamorelin transiently raises fasting glucose through GH-induced insulin resistance. This is reversible on discontinuation but requires monitoring, particularly in women with PCOS, a history of gestational diabetes, or pre-diabetes.
• Nausea and dysgeusia: Reported in early treatment weeks; typically resolves.

Women specifically should know that hormonal fluctuations during the menstrual cycle or perimenopausal transition may amplify some of these effects, particularly fluid retention and joint discomfort, though this has not been formally characterized in trials.

Practical Guidance: Branded vs Compounded Decision Checklist

Before accepting a tesamorelin prescription, whether branded or compounded, ask these specific questions:

1. Do I have an FDA-approved indication (HIV-associated lipodystrophy)?
2. If off-label: what is the evidence base, and what alternatives have been considered?
3. If compounded: what is the pharmacy's DEA and state board registration? Can they provide a third-party certificate of analysis for the current lot?
4. Have my baseline IGF-1, fasting glucose, HbA1c, and lipid panel been checked?
5. Is my contraceptive method in place and reliable if I am of reproductive age or in perimenopause?
6. Who will monitor my IGF-1 at 3 months and adjust or discontinue if I am above the sex- and age-adjusted upper limit of normal?

The North American Menopause Society does not currently have a position statement on tesamorelin for menopausal visceral adiposity, and ACOG has not issued guidance on tesamorelin off-label use. The absence of a guideline is itself clinical information.